Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Regeneron Pharmaceuticals (NQ: REGN ) 1,003.34 +2.55 (+0.25%) Streaming Delayed Price Updated: 3:58 PM EDT, Jun 7, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Regeneron Pharmaceuticals < Previous 1 2 3 4 5 6 Next > Dupixent® (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal Trial March 23, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire FDA Approves First-in-class Evkeeza® (evinacumab-dgnb) for Young Children with Ultra-rare Form of High Cholesterol March 22, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis March 21, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis March 18, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Students Win More Than $1.8 Million at 2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart Disease March 14, 2023 $250,000 top award goes to Neel Moudgal in the nation’s oldest and most prestigious science and math competition for high school seniors From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Dupixent® (dupilumab) Application for Treatment of Chronic Spontaneous Urticaria (CSU) in Adults and Adolescents Aged 12 Years and Older Accepted for FDA Review March 07, 2023 More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by antihistamines From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Kevzara® (sarilumab) Approved by FDA as First and Only Biologic Indicated for Patients with Polymyalgia Rheumatica February 28, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Libtayo® (cemiplimab) in Combination with Chemotherapy Receives Positive CHMP Opinion for the Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) February 24, 2023 Recommendation based on a Phase 3 trial demonstrating superior survival outcomes for Libtayo plus chemotherapy compared to chemotherapy alone From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Aflibercept 8 mg BLA for Treatment of Wet Age-Related Macular Degeneration and Diabetic Macular Edema Accepted for FDA Priority Review February 23, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Analyst Confidence in Eli Lilly Boosted by Product Pipeline February 22, 2023 Eli Lilly has long been a reliable stock, but with the company's impressive product pipeline, the stock could hold significant potential in the near term. Via MarketBeat 3 More Mid-Cap Biotechs The Street Sees Doubling February 22, 2023 According to Wall Street research groups, these three mid-cap biotechs have 2x potential. It’s for the investor to decide if the upside justifies the risk. Via MarketBeat Pozelimab (C5 Antibody) BLA for Treatment of Children and Adults with Ultra-rare CHAPLE Disease Accepted for FDA Priority Review February 21, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire EYLEA® (aflibercept) Injection Approved as the First Pharmacologic Treatment for Preterm Infants with Retinopathy of Prematurity (ROP) by the FDA February 08, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Is Biotech Immunocore About To Make A 25% Price Move? February 07, 2023 Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher. Via MarketBeat Topics ETFs Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results February 03, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron Announces Investor Conference Presentations January 31, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis January 30, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Dupixent® (dupilumab) Recommended for Expanded EU Approval by the CHMP to Treat Children as Young as Six Months Old with Severe Atopic Dermatitis January 27, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Top 40 High School Scientists Selected as Finalists in the Regeneron Science Talent Search, the Nation’s Oldest and Most Prestigious Science and Math Competition January 24, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Four Undervalued Healthcare Stocks for 2023 January 06, 2023 These four health care stocks could be undervalued: Pfizer Inc., Regeneron Pharmaceuticals Inc., Innoviva Inc. and Exelixis Inc. Via MarketBeat Exposures COVID-19 Regeneron to Report Fourth Quarter and Full Year 2022 Financial and Operating Results and Host Conference Call and Webcast on February 3, 2023 January 03, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire 3 Mid-Caps That Could Double in 2023 December 15, 2022 Mid-cap land has long been regarded as the ‘sweet spot’ for equity investors. Here are three mid-caps Wall Street sees as two-baggers over the next 12 months. Via MarketBeat Harpoon Therapeutics Remains Volatile After Promising News December 14, 2022 Harpoon Therapeutics offers an example of biotech's volatility. The stock advanced as much as 191% intraday Monday before settling down to a gain of 22.61%. Via MarketBeat CytomX Therapeutics (NASDAQ: CTMX) and Regeneron (NASDAQ: REGN) Enter into Strategic Collaboration to Develop Bispecific Therapies to Treat Cancer November 17, 2022 CytomX Therapeutics, Inc. (NASDAQ: CTMX) is a clinical-stage biopharmaceutical company, which is focused on developing innovative treatments for a wide-range Via Spotlight Growth Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report? November 11, 2022 Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel. Via MarketBeat Why These 3 Stocks Are Off to Hot September Starts September 13, 2022 Let’s look at what is behind the surprise rise in these three names—and whether they can continue to pace this month’s market rally. Via MarketBeat Topics Economy Exposures Economy Interest Rates Air Pollution is a Global Heart and Lung Health Concern July 18, 2022 Palm Beach, FL – July 18, 2022 – FinancialNewsMedia.com News Commentary – Particulate matter or particle pollution is a significant contributor to heart and lung disease. Individuals most affected by... Via FinancialNewsMedia Topics Climate Change Emissions Energy Exposures Climate Fossil Fuels NASDAQ:REGN Investor Notice: Investigation over Potential Wrongdoing at Regeneron Pharmaceuticals, Inc. May 31, 2022 San Diego, CA -- (SBWIRE) -- 05/31/2022 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at Regeneron Pharmaceuticals, Inc. Via SBWire NASDAQ: REGN Shareholder Notice: Investigation over Possible Securities Laws Violations by Regeneron Pharmaceuticals, Inc. April 15, 2022 San Diego, CA -- (SBWIRE) -- 04/15/2022 -- Regeneron Pharmaceuticals, Inc is under investigation over potential securities laws violations in connection with certain financial statements. Via SBWire Regeneron Pharmaceuticals Inc. (REGN) Climbs to Annual-High Share Price March 21, 2022 Via Investor Brand Network < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
